EnGeneIC Announces First Patient Dosed in Recurrent Glioblastoma Clinical Trial
Summary
SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s in...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.